Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyResearch in context
Summary: Background: Peripheral T-cell lymphoma (PTCL) represents a highly heterogeneous group of non-Hodgkin's lymphomas, often with aggressive biological behaviour. CD30 serves as a pivotal surface antigen in PTCL, however, its biological functions and therapeutic potential warrant further i...
Saved in:
| Main Authors: | Yu-Jia Huo, Shu Cheng, Hong-Mei Yi, Ting Niu, Lei Fan, Guo-Hui Cui, Fu-Ling Zhou, Xian-Min Song, Fei Li, Ou Bai, Xiao-Jing Yan, Jun Shi, Ming-Ci Cai, Yao-Hui Huang, Lei Dong, Jie Xiong, Song Hu, Yu-Ran Qiu, Yan Zhao, Peng-Peng Xu, Li Wang, Min Lu, Hong-Mei Jing, Wei-Li Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425001379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient
by: Adela Della Marina, et al.
Published: (2025-06-01) -
Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
by: Gen Hasegawa, et al.
Published: (2025-01-01) -
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01) -
Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01) -
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
by: Carrie van der Weyden, et al.
Published: (2025-06-01)